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Abstract
Introduction Clinical practice guidelines based on best available evidence and national safety and quality standards promote high
quality and safe care.
Aim To review and standardise systemic anti-cancer therapy (SACT) forms in a 20-chair cancer centre to reflect Australian and
international clinical practice guidelines.
Method A pre–post audit design based on Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing,
dispensing and administration of systemic cancer therapy underpinned the project. The pre-audit (47 forms) provided a benchmark for
SACT form improvements: 177 new forms were then developed over 18 months and implemented.
Results Pre-audit: 9/19 criteria were >70% compliant with best practice guidelines. Post-SACT implementation audit: 15/19 criteria were
>70% compliant. The recent 2018 audit: improvements shown in 18/19 criteria.
Conclusion This nurse-led multidisciplinary initiative effectively standardised SACT charts with best practice guidelines, potentially
reducing serious medication errors and facilitating a high standard of multidisciplinary patient care.

Background
Systemic anti-cancer therapy (SACT) is classified as a high-risk
medication and is predominantly used in complex anti-cancer
treatment regimens. SACT can cause fatal adverse toxicity
events even when used at therapeutic dosages due to narrow
therapeutic indices, complex anti-cancer treatment regimens,
and the vulnerable cancer patient population1,2. Despite the
known risks, medication errors related to incorrect prescribing,
preparation and/or administration remain relatively common
despite recent increased efforts to enhance patient safety1.
Ranchon et al.3 demonstrated in their prospective study of
6,607 antineoplastic prescriptions that 341 (5.2%) contained
at least one medication error (total errors n=449). Of these
errors, 436/449 were intercepted before the medication was
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administered to a patient. Prescription errors accounted for 91%
of errors, with 13.4% of avoided errors potentially resulting in
temporary injury and 2.6% in permanent injury.
The Pennsylvania Patient Safety Authority1 analysed 1,015
medication error events associated with haematology and
oncology outpatient departments over a 2-year period from June
2015 to June 2017. Medication events included antineoplastic
drugs, SACT pre-medication drugs, opioids and anticoagulants.
High alert medications – those that pose an increased risk of
patient harm when involved in medication errors – accounted
for 55.5% (n=563) of events; the most commonly prescribed
being antineoplastic agents (94.3%, n=531). More than half (53.7%,
n=545) of the events affected the patient and 43.3% (n=439)
were intercepted before reaching the patient. Errors occurred

most frequently during the prescribing and administration
processes. Car et al.4 recruited 40 North West London cancer
care clinicians to identify and prioritise perceived causal reasons
for, and solutions to, medication errors in cancer care using a
priority-setting approach. Thematic analysis revealed 20 distinct
problems and 22 solutions. Twenty-six clinicians from the original
cohort then ranked the composite list of perceived problems.
Improved communication between healthcare providers, quality
assurance procedures – during prescription and monitoring
stages – and patient education were identified as key strategies
for improving antineoplastic medication safety. The prescribing
stage was identified as most vulnerable to medication safety
threats. Banasser, Karpow, Gaunt and Grissinger5 suggested that
error reduction strategies in outpatient oncology clinics should
commence with a risk assessment of medication use processes
with a focus on communication and quality procedures during
the prescribing process.
There has been a notable shift in the evidence-based
international guidelines related to the administration of
SACT. Well-designed, standardised, regimen-specific SACT
order forms decrease potential errors by organising treatment
information in a clear, consistent and uniform format6. The use
of computerised prescriptions is now recommended as best
practice to reduce the risk of adverse events and that, in lieu of
computerised prescribing, standardised, pre-printed forms must
be used to maintain consistency, and that handwritten orders
are unacceptable6–11.
Leung et al.12 developed an evidence-based practice guideline for
the safe administration of SACT and management of preventable
adverse events for use in the Canadian Province of Ontario. The
guideline was influenced by the clinical expertise of the working
group members and multiple international SACT administration
guidelines including COSA’s guideline for the safe prescribing,
dispensing and administration of systemic cancer therapy9,
and eviQ’s timeout procedure checklist13 and clinical safety
procedure14. The quality of the Australian eviQ13,14 and COSA9
guidelines and other international guidelines was evaluated by
the working group using the Appraisal of Guidelines for Research
and Evaluation (AGREE) II Tool15. The guidelines were rated highly
across all domains12. Of note, the COSA guideline for the safe
prescribing, dispensing and administration of systemic cancer
therapy recommends that a fully validated electronic prescribing
system should be utilised for the prescribing of SACT wherever
available; if not, pre-printed prescriptions should be used9.
In Australia, the safe administration of SACT is guided by
the COSA guidelines for the safe prescribing, dispensing and
administration of systemic cancer therapy9 and eviQ’s online
evidence-based, consensus driven cancer treatment protocols
and information for use at the point of care.

Australian healthcare organisations are required to undergo
mandatory accreditation, the recognition by a healthcare
accreditation body of the achievement of eight quality and
safety standards through an external peer assessment process.
The National Safety and Quality Health Service (NSQHS)
standards are developed by the Australian Commission on
Safety and Quality in Health Care in consultation with the
Australian government, states and territories, the private health
sector, clinical experts, patients and carers16. The primary aim
of the NSQHS standards is to: protect the public from harm,
improve the quality of health service provision; and support
a quality assurance mechanism that tests whether relevant
systems are in place to ensure that expected standards of safety
and quality are met. The delivery of SACT is mandated by the
NSQHS standard 4, medication safety16, that requires SACT order
charts to reflect current best practice guidelines.
Consistent with other national and international tertiary
cancer treatment centres, SACT at the study site is constantly
evolving with the introduction of immunotherapies and targeted
therapies which are transforming treatment regimens for many
cancers. Prior to study commencement it was observed that
current SACT charts did not meet minimum Australian and
international best practice standards for the delivery of SACT.
Ethical issues
Approval to conduct this nurse-led study was granted by the
study site’s Human Research Ethics Committee. Approval was
based on a waiver of consent and contingent on the analysis
and presentation of aggregated data ensuring patient anonymity.

Plan, Do, Study, Act (PDSA) model for service
improvement
The Plan-Do-Study-Act (PDSA)17,18 framework guided development
and standardisation of SACT prescription forms. Stages of the
PDSA cycle are:
• Plan – determine the change to be tested or implemented
• Do – carry out the test or change
• Study – based on the measurable outcomes agreed before
commencement, collect data before and after the change
and reflect on the impact of the change and what was
learned
• Act – plan the next change cycle or full implementation19.
Prior to implementation, three guiding questions were
considered:
• What are we trying to accomplish (aim)?
• What measures of success will be used (audits)?
• What change concepts will be tested (best practice SACT
prescription forms)?
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Plan
The study was conducted in a 20-chair outpatient cancer
centre located within a large 507-bed private tertiary teaching
hospital in the southern corridor of the Perth metropolitan
area in Western Australia. The study site has witnessed a steady
increase in patient presentations over recent years from 4,500
in 2009/10 to >15,000 in 2017/18, with 10,384 episodes of anticancer treatment provided in 2018.
The SACT charts used prior to the study commencement were
developed in 2013 prior to the introduction of immunotherapies,
targeted biological therapies and current Australian and
international best practice SACT guidelines. This study aimed
to review, develop and standardise SACT prescription forms to
reflect current national and international best practice.
Do
In 2015 a multidisciplinary committee was convened to review
47 SACT order charts in use pre-study. Committee membership
comprised cancer nurses, oncology pharmacists, oncologists
and haematologists. SACT charts were compared against
the Cancer Institute New South Wales eviQ14, the National
Comprehensive Cancer Network (NCCN)20 and the British
Columbia Cancer agency (BC Cancer)21 protocols. The team
agreed that development of individual charts for each treatment
regimen (n=224) was required to reflect current best practice
and reduce the risk for adverse medication errors. A compliance
audit tool based on the COSA guidelines for the safe prescribing,
dispensing and administration of systemic cancer therapy9 was
developed and used to audit 50 SACT charts in June 2015. SACT
charts were randomly selected and audited over a 1-week period
to identify inconsistencies with best practice.
Study
Baseline audit results were disseminated and reviewed by
all committee members (Table 1). In consultation with the
multidisciplinary team, the study centre pharmacists assumed
responsibility for the process of revising 47 existing, and
developing 177 new, SACT prescription forms using the Cancer
Institute NSW standard cancer treatments (eviQ) guidelines14,
the NCCN20 and the BC Cancer chemotherapy guidelines21
protocols as reference tools. Two hundred and twenty-four
SACT forms were approved for circulation and patient use in
the cancer centre over an 18-month period between June 2015
and November 2016. Each SACT prescription chart was peer
reviewed by oncologists, haematologists, the nurse unit manager
(NUM) and an external lead pharmacist from a non-oncology
department within the hospital. The hospital’s Medication
Safety Committee advised that due to the specialised nature of
the SACT prescription forms, approval from the cancer centre
team was sufficient to proceed with the implementation of
the new forms. Prior to implementation in November 2016,
education was primarily provided to the multidisciplinary team
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by the lead oncology pharmacist via face-to-face meetings with
oncologists and haematologists to explain the changes to the
SACT prescription forms and the proposed implementation
process. All other staff were notified electronically via email
with the same information and requested to provide feedback
to the multidisciplinary committee. This feedback process
continues as an ongoing process.
Act
In February 2017 a repeat audit using the same audit tool was
undertaken with 50 randomly selected SACT charts over a
1-week period (Table 1). The results were disseminated to all
oncologists, haematologists, pharmacists and nursing staff.
Based on the four areas with the lowest compliance, a number
of interventions were employed. Further education was provided
by the chief pharmacist to oncologists and haematologists
to address key deficits identified by the audit via one-toone discussions. These physicians were encouraged to initial
and date treatment dose changes and to clearly identify the
treatment cycle, the most common deficits identified by the
audit. Nurses were requested not to accept incomplete SACT
order charts.

Results
Table 1 presents pre- and post-audit results. A compliance rate of
<70% requires immediate action; compliance between 70% and
85% indicates a need for improvement, and compliance >85%
signifies good compliance with best practice guidelines.
The pre-audit conducted in 2015 showed that only three
domains illustrated >85% compliance with current best practice
guidelines. More than 50% of domains showed a compliance
of <70% and highlighted a need for immediate action since
they indicated potential for serious adverse events for patients
receiving SACT. During the 18-month period when SACT charts
were being revised, oncologists and haematologists were
educated by the lead pharmacist regarding the COSA best
practice guidelines and expectations of them as prescribers of
anti-cancer therapy.
Results of the second audit performed in 2017 after the
standardised charts had been in use for 3 months showed an
improvement, with nine domains achieving good compliance
and only four domains illustrating poor compliance. The 2018
audit showed the cancer centre had achieved good compliance
in 14 domains, while the four areas with poor compliance
showed an overall improvement and highlighted areas where the
cancer centre needs to improve. The only area which has shown
a decrease in compliance between the 2017 and 2018 audits is
the accurate height, weight and body surface area (BSA) domain.
This is concerning as accurate dosing of anti-cancer therapy is
dependent on accurate BSAs. There is the potential for patients
to be underdosed, with resultant compromise of success of

Criteria

Compliance Compliance
Jun 2015
Feb 2017

Variance
s/t

Compliance
Aug 2018

Variance
s/t

UMRN sticker with hospital number, name, DOB

98%

98%

nil

98%

nil

Current height, weight and accurate BSA

42%

89%

s 47%

72%

t 17%

Computer-generated prescription (not handwritten)

82%

82%

nil

88%

s 6%

If handwritten, is the drug and dose clear and unambiguous?

50%

86%

s 36%

96%

s 10%

Is the drug dosing clear and do drug doses have appropriate measurements?

63%

78%

s 15%

92%

s 14%

Are the drugs prescribed clearly in the correct order?

80%

88%

s 8%

100%

s 12%

Has written consent been obtained?

0%

0%

nil

0%

nil

Is the chart signed and dated?

77%

96%

s 19%

100%

s 4%

Is the name of the regimen clear and appropriate?

61%

88%

s 27%

88%

nil

Is the cycle number clearly written?

49%

55%

s 6%

68%

s 13%

Is the route of administration clear?

89%

92%

s 3%

98%

s 6%

Is the tumour type and stage stated?

59%

74%

s 15%

92%

s 18%

Is the infusion rate clear?

77%

80%

s 3%

98%

s 18%

Is the diluent/compatible fluid clearly recorded?

75%

78%

s 3%

98%

s 20%

Are allergies clearly stated?

92%

94%

s 2%

98%

s 4%

Are dose changes initialled and dated?

2%

1%

t 1%

13%

s 12%

Are ‘crossings off’ initialled and dated?

4%

0%

t 4%

13%

s 13%

Are the required laboratory tests documented?

70%

88%

s 18%

89%

s 1%

Is supportive therapy charted unambiguously?

43%

77%

s 34%

98%

s 21%

UMRN = unit medical record number, DOB = date of birth, BSA = body surface area

the therapy, or overdosed and experience potentially fatal side
effects3. BSA is initially calculated by the prescribing doctor and
checked by the pharmacist, although nurses check the patient’s
weight at each cancer centre visit. If the weight has changed, the
nurse will recalculate the BSA and inform the prescriber. Nursing
staff will continue to receive education around completing this
calculation and support to return the chart to doctors if the
dosing is incorrect.
Of note, whilst ‘obtaining written consent’ was recorded as 0%
for each audit, this is because verbal, not written, consent was
gained from patients during the period covered by the audit.
Since 2018, the practice has changed to ensure the written
consent form is kept with the patient’s SACT prescription.
A patient safety analysis of 1,015 medication errors reported
in the Pennsylvania Patient Safety Reporting System from
outpatient haematology and oncology clinics5 illustrated that
dosage errors were mostly attributed to inaccurate patient
weights; this was also a finding of our quality initiative. Current
patient information is therefore essential to guide accurate
prescribing.
Currently, in 2019, the standardised SACT charts remain in use
within the cancer centre. The success of this initiative has
prompted standardisation of SACT charts across all of the

organisation’s Western Australian divisions who administer SACT,
with the new chart considered the benchmark.

Discussion
Adherence to best practice SACT guidelines ensures safe and
high quality care for patients receiving anti-cancer therapies
in an outpatient cancer setting. This nurse-led study has
demonstrated how a systematic approach has produced
clinically significant improvements in multidisciplinary practice
through implementation of standardised SACT prescription
forms. Importantly, this change in practice has reduced the
potential for serious medication errors.
Notwithstanding the positive outcomes of this study,
improvement is still required in some areas. It is proposed that
continued application of this collaborative multidisciplinary
approach can facilitate improvement in a number of ways. It
is essential the cancer centre adopts a strong culture of safety
and quality. We recommend that cancer nurses, oncologists
and pharmacists are provided with continuous education about
the requirements of SACT prescription charts as per current
best practice national and international guidelines. Nurses and
pharmacy staff must be encouraged and supported to ‘refuse
to accept and use’ incomplete SACT prescription charts. The
cancer centre is also committed to performing an annual audit
and review of the forms in order to standardise SACT forms
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and minimise the risk of medication errors and patient harm.
Electronic SACT prescribing is due to be introduced to the
cancer centre in the near future and will further embed the
culture of safety and quality we strive to maintain.

10. Ghaibi S, Ipema H, Gabay M. ASHP guidelines on the pharmacist’s role in
providing drug information. Am J Health-Syst Pharm 2015;72:573–7.

Recommendations

12. Leung M, Bland R, Baldassarre F, Green E, Kaizer L, Hertz S, et al. Part 2:
Administration of systemic treatment and management of preventable
adverse events. Program in Evidence-based Care Practice Guideline
Report No: 12-12-2. ed. Toronto (ON): Cancer Care Ontario; 2018 Nov 30.

• P erform an annual audit and review of SACT prescription
forms.
• M
 aintain multidisciplinary team education to ensure best
practice prescribing and administration of SACT.;
• C
 ontinue peer review of SACT prescription forms as new
SACT become available.
• E nsure SACT prescription forms are used as the benchmark
for the organisation’s other Western Australian cancer centres
to prevent and/or minimise medication errors.
• C
 ontinuously review both actual and near miss medication
errors in order to implement further risk prevention strategies
to reduce errors for this high risk population.
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